ClinPGx Blog (Page 22)

Sign in Subscribe

More issues

NHGRI’s Genomic Medicine X: Pharmacogenomics Meeting

On May 2 and 3, 2017, the National Human Genome Research Institute (NHGRI) held its 10th Genomic Medicine meeting, focusing on pharmacogenomics. PharmGKB, PharmCAT and CPIC were presented, as well as a review of the deposition of PharmGKB and CPIC data to ClinVar. We thank Mary Relling from St Jude

Curators' Favorite Papers

Electronic medical record-integrated pharmacogenomics and related clinical decision support concepts Authors: Caraballo PJ Bielinski SJ St Sauver JL Weinshilboum RM The authors of this article from Clinical Pharmacology and Therapeutics, discuss the challenges to successful integration of pharmacogenetic/pharmacogenomic (PGx) clinical decision support (CDS) tools into electronic health and medical

March for Science

On April 22, 2017 — members of the PharmGKB team, participated with thousands of other scientists and non-scientists alike, in the March for Science. Please join us, as did Russ Altman (Co-Prinicipal Investigator, PharmGKB) and the larger scientific community in the continuation of evidence-based science.

Thiopurine Pathway updated with new candidate genes

Thiopurines and TPMT have long been a cornerstone of PGx research. As such the Thiopurine Pathway was one of the earliest pathways in PharmGKB to be published in Pharmacogenetics and Genomics [PMID:19952870]. In collaboration with Jun Yang, Takaya Moriyama and Rina Nishii from St Judes, we have substantially updated

Sorafenib pathways published in Pharmacogenetics and Genomics

The PharmGKB review of the Sorafenib pathways has been published in the journal Pharmacogenetics and Genomics. Sorafenib (NEXAVAR®, BAY43-9006) is an oral anti-cancer drug approved for the treatment of metastatic or advanced liver, kidney, and thyroid cancers. Although many new targeted therapies have been tested over the past decade, sorafenib

NIGMS Director’s Early Career Investigator Lecture on antiretrovirals, PGx

On Wednesday, April 5th at 2:00 PM EST the National Institute of General Medical Sciences (NIGMS) will broadcast the NIGMS Director’s Early Career Investigator Lecture featuring a talk by Dr. Namandjé N. Bumpus entitled “Drug Metabolism, Pharmacogenetics and the Quest to Personalize HIV Treatment and Prevention”. In it,

New Paper shows pharmacogenetic testing drastically reduces ER visits and Readmissions

A new paper published in PLOSOne (Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial by Lindsay S. Elliott et al.) shows the effectiveness of precision medicine. For a year the authors followed a set of eligible

Congratulations to Dr. Teri Klein!

PharmGKB is pleased to announce that the Stanford Provost has approved Dr. Teri Klein’s appointment as a Professor of Biomedical Data Science! This appointment is effective March 1 and represents a great acknowledgement of Teri’s academic contributions and leadership in data science and pharmacogenomics. Teri and Russ Altman

CPIC Guideline Update: CYP2C9/VKORC1/CYP4F2 and Warfarin

The 2017 update of CPIC guideline for pharmacogenetics-guided warfarin dosing has been accepted for publication in Clinical Pharmacology and Therapeutics. CPIC extensively reviewed the literature up to Dec 2016. Both the dosing recommendations and supplemental information were updated. The accepted article can currently be viewed on the PharmGKB and CPIC

New PharmGKB pathway: macrolide antibiotics pharmacokinetics/pharmacodynamics

The PharmGKB summary of the pharmacokinetics and pharmacodynamics of macrolide antibiotics has been published in Pharmacogenetics and Genomics. This summary introduces the candidate genes involved in the pharmacokinetic and pharmacodynamic pathways of macrolide antibiotics, focusing on erythromycin, clarithromycin, and azithromycin. We present the uptake, transport, metabolism and clearance of the